Fixed-dose combination of laroprovstat/rosuvastatin vs rosuvastatin alone for high cholesterol

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 trial compares multiple fixed-dose combinations of laroprovstat/rosuvastatin to rosuvastatin and placebo in adults with hypercholesterolaemia. Participants must be on a stable statin dose at their maximum tolerated level and have either a prior ASCVD event or high risk for a first event. The study will measure changes in LDL-C and assess safety and tolerability. Sites are located in Arizona and California under the lead sponsorship of AstraZeneca. The intervention arms include several dose combinations of laroprovstat/rosuvastatin and matching placebos.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant must be ≥ 18 years of age
* Participants must be on a stable dose of all background LLTs
* The stable statin dose should be judged as their maximally tolerated dose
* Participants should have either history of a clinical ASCVD event or be at increased risk for a first clinical ASCVD event

Exclusion Criteria:

* Asian origin
* Uncontrolled severe hypertension
* Uncontrolled T2DM
* Inadequately treated hypothyroidism

Where it's running

• Research Site
  Sun City West, Arizona, United States Recruiting
• Research Site
  Pomona, California, United States Recruiting
• Research Site
  Miami Lakes, Florida, United States Recruiting
• Research Site
  Conyers, Georgia, United States Recruiting
• Research Site
  Decatur, Georgia, United States Recruiting
• Research Site
  Beltsville, Maryland, United States Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Linking social care with healthcare to help manage chronic diseases

  This trial tests whether pairing patients with trained community health workers can help them get transportation, healthy food, information, and better access to care to improve health in conditions like hypertension, diabetes, and high cholesterol.

  Recruiting at 2 sites University of Arizona · Tucson, Arizona and 1 other locations · NCT07799961

• A new combination pill to lower LDL cholesterol in adults who haven’t taken cholesterol medicine before

  This study tests whether a fixed-dose combo pill of laroprovstat and rosuvastatin can lower LDL-C better than laroprovstat alone, rosuvastatin alone, or placebo in adults without prior lipid therapy.

  Recruiting at 12 sites Phase 3 AstraZeneca · Dothan, Alabama and 151 other locations · NCT07619131

• Obicetrapib vs. bempedoic acid for high-risk high cholesterol patients

  This phase 3 study tests whether obicetrapib can lower LDL-C more than bempedoic acid in adults with primary non-familial hypercholesterolemia or mixed dyslipidemia who still have high LDL-C despite maximum tolerated therapy.

  Recruiting Phase 3 A. Menarini International Licensing S.A. · Stockton-on-Tees · NCT07614958

• Combination therapy with QCZ484 and Inclisiran for hypertension with high cholesterol

  This study tests whether the drug QCZ484, alone or with Inclisiran, lowers cholesterol and helps blood pressure in adults with hypertension and high cholesterol.

  Recruiting at 29 sites Phase 2 Novartis · Foley, Alabama and 28 other locations · NCT07610278

• CTX310 for refractory high triglycerides or LDL cholesterol

  This trial will test whether a single IV dose of CTX310 is safe and tolerated in adults whose high triglycerides or LDL cholesterol have not responded to available treatments.

  Recruiting at 16 sites Phase 1 CRISPR Therapeutics · Hialeah, Florida and 16 other locations · NCT07491172

• Adherence, persistence, and real-life effectiveness of alirocumab 300 mg for people with high cholesterol in Italy

  This project will test whether alirocumab 300 mg helps people with high cholesterol in Italy stick with their treatment and lower their cholesterol when used in routine care.

  Recruiting Federico II University · Naples, Napoli · NCT07375225

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.